FIGURE 2.

IRGPI was tightly associated with genomic alterations and molecular subtypes of bladder cancers. (A) OncoPrint showing mutational landscape of 15 bladder cancer drivers. (B and C) Barplots showing the similar distribution of TP53 and FGFR3 mutations in different risk groups in GSE32548 cohort (TP53: 69.8% vs. 43.8%, p = .004; FGFR3: 17.5% vs. 59.4%, p < .001) and UTUC cohort (TP53: 16.7% vs. 37.5%, p > .05; FGFR3: 66.7% vs. 12.5%, p = .091), respectively. (D) The consensus subtype frequency of cohort‐specific risk groups across nine cohorts. (E) Forest plot revealed that IRGPI was an independent prognostic factor after adjusting molecular subtypes, TP53 and FGFR3 mutations